UNSPSC 51171942: Gefarnate

This classification denotes an antispasmotic agent with the molecular formula C27H44O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1ISE2Y6ULA, chemically known as 5,9,13-trimethyl-4,8,12-tetradecatrienoic acid 3,7-dimethyl-2,6-octadienyl ester but generally known as gefarnate, which bears US NIH Compound Identifier 5282182. European Medicines Agency schedules Gefarnate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07889MIG. The term GEFARNATE is an International Non-Proprietary Name.

UNSPSC 51171942 Gefarnate, a Commodity code, has minimal documented state and local procurement activity. The three recent opportunities tagged under this code span specimen collection and drug testing services, direct-to-manufacturer pharmaceutical programs, and generic multi-source pharmaceutical distribution — none of which align with gefarnate, a pharmaceutical compound used primarily as a gastric mucosal protectant in clinical settings. The mismatch between the code's nominal scope and the actual work being solicited suggests that state and local procurement offices are not using this code to buy gefarnate as a finished product or raw material. No recent solicitations specifically request gefarnate procurement.

The three opportunities present in the dataset span Texas and Minnesota jurisdictions but represent pharmaceutical services and generic drug distribution rather than gefarnate supply. Collin County Community Supervision and Corrections Department issued RFP 2026-327 (due July 23, 2026) for offender specimen collection and drug testing services, estimated at $600,000 over two years with optional renewals. The Texas Health and Human Services Commission posted RFI HHS0017013 in March 2026 to explore direct-to-manufacturer prescription fulfillment models, seeking vendor capabilities for state pharmacy benefit programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers across state and local facilities in Minnesota and Oregon. These solicitations reflect demand for pharmaceutical services infrastructure, testing operations, and generic drug distribution channels rather than gefarnate as a procured commodity. The code shows little relevant recent activity for firms supplying gefarnate to state and local buyers.